Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DRRX DURECT	$0.54 +2.1%	$0.60	$0.48 ▼ $1.74	$16.27M	0.64	50,032 shs	40,385 shs
LPCN Lipocine	$3.12 -1.6%	$3.28	$2.68 ▼ $7.18	$16.96M	1.3	33,058 shs	58,457 shs
PMN Promis Neurosciences	$0.44 -6.4%	$0.48	$0.38 ▼ $2.20	$15.37M	-0.1	498,877 shs	395,808 shs
SPRB Spruce Biosciences	$0.11 +15.8%	$0.07	$0.06 ▼ $0.61	$4.65M	2.4	690,496 shs	146,692 shs

The 10 Best AI Stocks to Own in 2025

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DRRX DURECT	+2.14%	-14.45%	-18.49%	-28.22%	-62.83%
LPCN Lipocine	-1.58%	-4.59%	-2.50%	+4.00%	-51.10%
PMN Promis Neurosciences	-6.38%	+12.73%	-11.98%	-30.69%	-79.53%
SPRB Spruce Biosciences	+15.79%	+23.04%	+52.99%	-7.33%	-80.43%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
DRRX DURECT	0.4991 of 5 stars	0.0	3.0	4.4	0.0	0.0	0.0
LPCN Lipocine	2.906 of 5 stars	3.5	5.0	0.0	2.7	0.0	0.6
PMN Promis Neurosciences	3.1529 of 5 stars	3.5	4.0	0.0	2.5	0.8	1.3
SPRB Spruce Biosciences	2.4697 of 5 stars	3.0	3.0	0.0	0.0	1.7	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DRRX DURECT	2.00	Hold	N/A	N/A
LPCN Lipocine	3.00	Buy	$9.00	188.46% Upside
PMN Promis Neurosciences	3.00	Buy	$4.33	884.62% Upside
SPRB Spruce Biosciences	2.00	Hold	$1.75	1,490.91% Upside

Current Analyst Ratings Breakdown

Latest SPRB, DRRX, LPCN, and PMN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/14/2025	PMN Promis Neurosciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$4.00
7/14/2025	PMN Promis Neurosciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$4.00
6/27/2025	LPCN Lipocine	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$8.00
6/10/2025	LPCN Lipocine	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$8.00
5/29/2025	LPCN Lipocine	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy	$8.00
5/12/2025	PMN Promis Neurosciences	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$3.00

(Data available from 7/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DRRX DURECT	$2.03M	8.19	N/A	N/A	$0.29 per share	1.85
LPCN Lipocine	$11.20M	1.49	N/A	N/A	$3.93 per share	0.79
PMN Promis Neurosciences	N/A	N/A	N/A	N/A	$0.50 per share	N/A
SPRB Spruce Biosciences	$4.91M	0.95	N/A	N/A	$1.88 per share	0.06

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DRRX DURECT	-$8.32M	-$0.15	N/A	N/A	N/A	-91.54%	-267.36%	-64.00%	8/12/2025 (Estimated)
LPCN Lipocine	$10K	-$1.02	N/A	∞	N/A	N/A	-26.68%	-24.77%	8/6/2025 (Estimated)
PMN Promis Neurosciences	$2.78M	-$0.05	N/A	N/A	N/A	N/A	-186.19%	-98.56%	8/6/2025 (Estimated)
SPRB Spruce Biosciences	-$47.92M	-$1.32	N/A	N/A	N/A	-555.23%	-62.10%	-47.49%	8/11/2025 (Estimated)

Latest SPRB, DRRX, LPCN, and PMN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q1 2025	LPCN Lipocine	-$0.41	N/A	N/A	N/A	$0.23 million	N/A
8/14/2025	Q2 2025	PMN Promis Neurosciences	-$0.22	N/A	N/A	N/A	N/A	N/A
8/12/2025	Q2 2025	DRRX DURECT	-$0.13	N/A	N/A	N/A	$0.32 million	N/A
8/11/2025	Q2 2025	SPRB Spruce Biosciences	-$0.25	N/A	N/A	N/A	$0.67 million	N/A
5/12/2025	Q1 2025	PMN Promis Neurosciences	-$0.14	-$0.21	-$0.07	-$0.21	N/A	N/A
5/8/2025	Q4 2024	LPCN Lipocine	-$0.35	-$0.35	N/A	-$0.35	$0.35 million	$0.09 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
DRRX DURECT	N/A	N/A	N/A	N/A	N/A
LPCN Lipocine	N/A	N/A	N/A	N/A	N/A
PMN Promis Neurosciences	N/A	N/A	N/A	N/A	N/A
SPRB Spruce Biosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DRRX DURECT	N/A	1.23	1.22
LPCN Lipocine	N/A	15.64	15.64
PMN Promis Neurosciences	N/A	3.36	3.36
SPRB Spruce Biosciences	0.01	5.36	5.36

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
DRRX DURECT	28.03%
LPCN Lipocine	9.11%
PMN Promis Neurosciences	50.13%
SPRB Spruce Biosciences	91.71%

Insider Ownership

Company	Insider Ownership
DRRX DURECT	3.20%
LPCN Lipocine	6.35%
PMN Promis Neurosciences	6.11%
SPRB Spruce Biosciences	6.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
DRRX DURECT	80	31.04 million	30.05 million	Optionable
LPCN Lipocine	10	5.35 million	5.01 million	No Data
PMN Promis Neurosciences	5	32.69 million	30.69 million	Not Optionable
SPRB Spruce Biosciences	20	42.23 million	37.54 million	Optionable

SPRB, DRRX, LPCN, and PMN Headlines

Recent News About These Companies

SPRB Spruce Biosciences, Inc. - Seeking Alpha

June 24, 2025 | seekingalpha.com

Spruce Biosciences gets conditional approval to resume trading on Nasdaq Capital Market

June 13, 2025 | msn.com

Spruce Biosciences Announces Conditional Nasdaq Approval to Resume Trading on the Nasdaq Capital Market

June 12, 2025 | finance.yahoo.com

Spruce Biosciences’ Compliance Plan Accepted by Nasdaq

June 12, 2025 | tipranks.com

Spruce Biosciences’ SWOT analysis: stock pivots amid clinical setbacks

May 7, 2025 | investing.com

Spruce Biosciences Inc Ordinary Shares

May 6, 2025 | morningstar.comM

Spruce Biosciences Reports First Quarter 2025 Financial Results and Provides Corporate Updates

May 6, 2025 | finance.yahoo.com

Spruce Axes 55% of Staff, Leaving Shoestring Crew To Focus on New Rare Disease Asset

April 28, 2025 | biospace.comB

Spruce halves head count, narrowing focus to get ex-BioMarin drug to FDA

April 28, 2025 | fiercebiotech.comF

Spruce Biosciences (SPRB) Receives a Hold from RBC Capital

April 17, 2025 | markets.businessinsider.com

Spruce Biosciences, Inc. (NASDAQ:SPRB) Q1 2023 Earnings Call Transcript

April 17, 2025 | insidermonkey.com

Spruce Biosciences Announces New Corporate Strategy and Acquisition of Tralesinidase Alfa for the Treatment of Sanfilippo Syndrome Type B (MPS IIIB)

April 15, 2025 | standard-journal.comS

With BioMarin deal, Spruce Biosciences hits reset on rare-disease drug

April 15, 2025 | bizjournals.com

Spruce Biosciences, Inc. (SPRB) Corporate Update Conference Call (Transcript)

April 15, 2025 | seekingalpha.com

Spruce Biosciences reports delayed annual filing

April 3, 2025 | investing.com

Spruce Biosciences Inc (SPRB) Stock: Understanding Its Underlying Value

February 5, 2025 | bovnews.comB

Hold Rating for Spruce Biosciences Amid Clinical Setbacks and Strategic Uncertainties

December 16, 2024 | markets.businessinsider.com

Spruce Biosciences (SPRB) Upgraded to Buy: Here's Why

December 13, 2024 | zacks.com

JMP Securities Downgrades Spruce Biosciences (SPRB)

December 12, 2024 | msn.com

Spruce saws off only drug after 2nd hyperplasia fail, leaving biotech's direction in doubt

December 11, 2024 | fiercebiotech.comF

New MarketBeat Followers Over Time

Media Sentiment Over Time

SPRB, DRRX, LPCN, and PMN Company Descriptions

DURECT NASDAQ:DRRX

$0.54 +0.01 (+2.14%)

As of 07/18/2025 04:00 PM Eastern

DURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program. The company's lead product larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis. It also offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. In addition, the company offers POSIMIR, a post-surgical pain product to deliver bupivacaine over three days in adults; and Methydur to treat attention deficit hyperactivity disorder. It markets and sells its ALZET lines through direct sales force in the United States, as well as through a network of distributors in other countries. The company has strategic collaboration and other agreements with Virginia Commonwealth University Intellectual Property Foundation; Indivior UK Ltd.; and Innocoll Pharmaceuticals Limited. DURECT Corporation was incorporated in 1998 and is headquartered in Cupertino, California.

Lipocine NASDAQ:LPCN

$3.12 -0.05 (-1.58%)

Closing price 07/18/2025 03:53 PM Eastern

Extended Trading

$3.20 +0.08 (+2.56%)

As of 07/18/2025 07:59 PM Eastern

Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. The company's pipeline candidates also include TLANDO XR a candidate for oral TRT for once daily dosing, which has completed Phase 2b clinical study; LPCN 1148, an oral prodrug of bioidentical testosterone, being developed for the treatment of cirrhosis, currently under Phase 2 clinical studies; LPCN 1154, An oral neurosteroid, being developed for the treatment of postpartum depression, currently under Phase 2 studies; LPCN 2101, a NAS candidate, for women with epilepsy; and LPCN 2203 for essential tremor. It is also involved in the development of LPCN 1144, an oral prodrug of bioidentical testosterone for the treatment of pre-cirrhotic non-alcoholic steatohepatitis, which has completed Phase 2 testing; and LPCN 1107, an oral product candidate of 17-alpha-hydroxy progesterone caproate product, currently under Phase 3 studies for the prevention of recurrent preterm birth. The company was founded in 1997 and is headquartered in Salt Lake City, Utah.

Promis Neurosciences NASDAQ:PMN

$0.44 -0.03 (-6.38%)

Closing price 07/18/2025 03:59 PM Eastern

Extended Trading

$0.42 -0.02 (-5.48%)

As of 07/18/2025 07:58 PM Eastern

ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates comprise of PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a TDP-43; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.

Spruce Biosciences NASDAQ:SPRB

$0.11 +0.02 (+15.79%)

As of 07/18/2025 03:32 PM Eastern

Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. Spruce Biosciences, Inc. has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses; and collaboration and license agreement with Kaken Pharmaceutical Co. Ltd. to develop, manufacture, and commercialize tildacerfont for the treatment of CAH in Japan. The company was incorporated in 2014 and is headquartered in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time